Key result
Atenolol use was associated with a significantly lower all-cause mortality rate compared to non-use among Asian patients with chronic progressive diseases (OR 0.57; 95% CI 0.44-0.75; P<0.001).
Why the study?
The study was conducted to determine the effectiveness of atenolol on all-cause mortality rate among Asian patients with chronic progressive diseases, mainly diabetes mellitus, primary hypertension, and coronary artery disease.
Does atenolol reduce all-cause mortality in Asian patients with chronic progressive diseases?
Meta-Analysis (n=79,603)
Does atenolol reduce all-cause mortality in Asian patients with chronic progressive diseases?
Atenolol is associated with a significant reduction in all-cause mortality compared to non-use or metoprolol tartrate in Asian patients with chronic progressive diseases.
May support atenolol consideration in Asian patients with chronic progressive diseases; leaves open confirmation in randomized trials.
Background: The current review was conducted to determine the effectiveness of atenolol on all-cause mortality rate among Asian patients with chronic progressive diseases, mainly diabetes mellitus, primary hypertension, and coronary artery disease. Methods: We searched the COCHRANE, MEDLINE, TRIP, and EMBASE databases for published articles up to 31 March 2023. Studies that compared all-cause mortality rates among Asian patients who were on atenolol or other medications were included. Results: The review included 79603 Asian patients from three cohort studies. Out of the studied patients, 36046 were atenolol users and 43557 were non-atenolol users. The review revealed that atenolol users recorded lower all-cause mortality rates compared to non-users with a significant difference (OR= 0.57, CI= 0.44-0.75, P<0.001). The pooled estimate of the all-cause mortality rate was also lower among atenolol users (7.02%) compared to metoprolol tartrate users (13.15%) with a significant difference (OR= 0.50, CI= 0.47-0.53, p < 0.0001). Although the included studies were categorized as having a low risk of bias for most of the studied domains, significant heterogeneity was recorded across these studies (I2 =88%, P=0.001). Conclusion: This review found that atenolol when compared to a control or metoprolol tartrate, has a significant effect in reducing the all-cause mortality rate among Asian patients with chronic progressive disease.
No takes yet. Share an insight, caveat, or question.
Alkattan et al. (2023) conducted a meta-analysis in Chronic progressive diseases (n=79,603). Atenolol vs. Non-atenolol users or metoprolol tartrate users was evaluated on All-cause mortality (OR 0.57, 95% CI 0.44-0.75, p=<0.001). Atenolol use was associated with a significantly lower all-cause mortality rate compared to non-use among Asian patients with chronic progressive diseases (OR 0.57; 95% CI 0.44-0.75; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: